Suitable agents for the regulation of blood glucose, and thus for treatment of non-insulin-dependent type II diabetes mellitus (NIDDM), include inhibitors of glucose-6-phosphate translocase (G-6-P-Tl)1}. This enzyme forms part of the glucose-6-phosphatase system (EC 3.1.3.9) , which is responsible for the formation of endogenous glucose originating from both, from gluconeogenesis and glycogenolysis.
The hepatic release of glucose from G-6-P, the common last step of both pathways is catalyzed by glucose-6-phosphatase (EC 3.1.3.9 ). Glucose-6-phosphatase is an enzyme complex made up of glucose-6-phosphate translocase (G-6-P-T1), glucose-6-phosphatase, and a phosphate translocase2). One of these components, G-6-P-T1 is highly selective, and is therefore a suitable target for the control of hepatic glucose release.
In the light of recent results suggesting that not even intensive pharmacological intervention with insulin or sulfonylureas in NIDDMachieves the goal of near-normal glycemia3), research into alternative therapeutic approaches pp.354 -363 is clearly justified. N. V S. Ramakrishna et al. discovered an inhibitor4) of glucose-6-phosphate translocase in cultures of a microorganism, HIL-008003, (DSM 11641) which they called mumbaistatin (1) . Although they succeeded in isolating the active principle, they were unable to determine the structure of this acid-labile compound,whose^-NMR spectrum contained relatively few signals. Wenow report a rational isolation procedure for mumbaistatin and describe the characterization of structure 1 on the basis of a singlecrystal X-ray structure analysis of the cyclized methylation product 2.
Materials and Methods
General Quantitative ultraviolet absorption spectra were recorded using a Cary 118 B spectrometer (Varian, Darmstadt, Table 3 . NMRspectroscopy NMR spectra were recorded on Bruker DRX 600 spectrometers operating at 600MHz (*H) and 150MHz (13C). Data were processed on an indigo2 station (Silicon Graphics) using Bruker XWINNMR software. Homonuclear COSY7)and ROESY8) experiments were performed with a spectral width of 7ppm. In all experiments, spectra were recorded with 5 12 increments in t and 4096 complex data points in t2. With regard to the nature of mumbaistatin, although the UVand IR spectra pointed to the presence of a quinoid system, the structure of the native inhibitor could only be deduced in part by NMR spectroscopy. Owing to the presence in solution of various species in equilibrium with one another, we were unable to find any experimental conditions that afforded high resolution *H or 13C spectra.
In fact, under acidic conditions mumbaistatin is largely converted into a non-polar form about one thousand times less biologically active than the unchanged natural product4'11\ Thus, to limit the number of possible forms, mumbaistatin was methylated by treatment with diazomethane in methanolic solution. This gave more than 10 reaction products, which were separated by reversedphase chromatography. The methylation product 2 crystallized from aqueous acetonitrile solution, as shown below, it is formed from mumbaistatin by cyclization and loss of water. This transformation is accompanied by changes in the UV absorption spectrum, which has maxima at 268, 323, and 392 nm at neutral pH. Product 3, molecular weight 590 Da, has a UVspectrum similar to that of mumbaistatin itself, and is a trimethyl derivative of the unchanged inhibitor. However, because of the facile decomposition of this activated ester, its structure could not be fully characterized. Product 4, molecular weight 586 Da, in turn has the same UVspectrum as compound2, and is clearly the tetramethyl derivative of the self-condensation product obtained by loss of water.
X-Ray Structure of Compound2
The X-ray diffraction pattern shows the systematic absences of the space group P21/c within the usual standard deviations.
It was possible to 'solve' the crystal structure in this space group. The "resulting molecule" had three chiral centers. It was also possible to 'refine' the structure in this space group: wR2=21.2%;the minimumand maximumin Fig. 2 . In the structure shown mumbaistatin can be seen to have undergone a triple methylation with loss of water, with two molecules present in the asymmetric unit cell. The actual 'absolute structure' could not be determined by our data, since there is no atom with enough anomalous scattering; weassumedthat the chiral center at C26 is analogous to that in juglorubin12). Based on this assumption, C126 and C226 were assigned an (S) configuration. The content of the asymmetric unit is shown in Fig. 2 . The two molecules have different configurations, (S, R, R) and (S, S, S), i.e. the crystals obtained are formed by cocrystallization of two diastereomers. Least-squares fits for the noncentrosymmetric and original centrosymmetric structures are shown in Fig. 3 . As can be seen, the different configurations of C126 and C226 give rise to only very minor differences. Using a rotating anode combined with a CCDdetector, we were able to calculate these slight differences in the scattered X-ray intensities with extremely high significance, even though we had to use a tiny crystal with dimensions of 0.2X0.1 X0.04mm. However, on closer examination, a few moreslight differences in the conformations of the two molecules in the asymmetric unit emerge, which prove that the two molecules in the asymmetric unit really are independent. The 'C26' atoms are now out of the planes of their 'heavy atom' substituents in the usual kind (0.512 and 0.535 A respectively). The planes of the phenyl rings of the resp ectively. Details of the crystal structure are shownin Fig. 4 . As can be seen, the molecules are oriented such that the anthraquinone subunits form sheets alternating in the crystallographic c-direction with sheets formed by the remainder of the molecule. These sheets are madeup of stacks parallel to the crystallographic a-axis. Neighboring molecules within the stacks are antiparallel.
Running parallel between the stacked anthraquinone sheets are channels containing the acetonitrile solvent molecules (one acetonitrile per mumbaistatin molecule). Acetonitrile seems to have only quasi-space filling purposes. The single hydroxy group is involved in an intramolecular hydrogen bond (O04H...O05: 2.55 and 2.58 A respectively). As mentioned above, the structure described is not that ofmumbaistatin itself, but of a methylated derivative. Fig. 1 most probably describes the reaction of the native mumbaistatin to give its cyclized spiro diketal lactone form (2) during the methylation.
The reaction scheme shows that methylation and intramolecular condensation of the molecule leads to the gain of two new chiral centers at the spiro junctions, with preservation of the chiral center at C26. Thus, in theory we should obtain four diastereomers, but we observe only two.
One possible explanation for this is that only these two diastereomers crystallize out. However, this is not consistent with the NMR spectra, as the fraction investigated shows only two sets of signals and not four.
It is possible that different steric hindrances of the different possible molecular conformations before the condensation and/or polarity differences might always induce the same two combinations of chiral centers, which can be considered as only one pair of local enantiomers. The structural characterization of 'free' mumbaistatin by NMRspectroscopy was hampered by the observation of broad signals, especially in the carbon spectrum. With the aid of COSY,HMQC, and HMBC spectra, we were able to assign three substructures. The first comprised the anthraquinone system C1-C14, the second the aromatic ring C17-C22, and the third the linear side chain from C24 to C28. However, owing to the small number of correlations in the HMBCand ROESYspectra, the way these fragments are linked could not be identified unambiguously.
To improve the quality of the NMRspectra, we decided to methylate the compound.Since the compoundcontains a large number of hydroxyl and two carboxy functions this chemical modification would be expected to reduce the signal broadening, which could be due to the presence in solution of several isomeric forms. As described above, one of the methylation products was crystallized and its X-ray structure was solved (see above and Fig. 2 ). The molecular formula of this methylation product 2 reveals the addition of three methyl groups and the loss of one molecule of water with respect to mumbaistatin. However, analysis of the NMRdata of 'free' mumbaistatin indicated that mumbaistatin is not simply the hydrolysis product of the lactone structure. In the cyclized product 4, the chemical shifts of the proton at position 26 are shifted significantly towards lower field with respect to mumbaistatin. On the other hand, in the dehydration products, the chemical shift of the protons at position 24 are shifted towards higher field. Furthermore, the 13C spectrum of mumbaistatin in CD3ODshows two very broad signals at -214. 3 and -198.4 ppm, indicating the presence of two keto functions. In the HMBC spectrum the signal at 214.3ppmshows a very weak coupling to one of the protons at position 25 (coupling to the protons at position 24 is not observed since these protons experience extreme linebroadening). å . ' , Taking these observations into account, it was deduced that the structure of mumbaistatin is that shown in Fig. 5 (left side). The broad signals in the NMRspectra might be explained by an equilibrium between the 'diketo' and ' spiroketal lactone' forms.
Having established the structures of mumbaistatin 1 and its derivative 2 by NMRand X-ray diffraction methods, we were able to determine the structures of a further methylation products on the basis of their NMRdata. Like all cyclized derivatives of mumbaistatin the tetramethyl derivative 4 shows two sets of signals in its NMRspectra arising from the presence of different diastereomers (ratio 1.2: 1.0) . Because the methylation led to a significant improvement in the quality of the NMRspectra, we were able to completely assign all the NMR signals. The positions of all four methoxy groups were confirmed by correlations in the HMBC spectrum.
Discussion
Mumbaistatin is a novel compound with a structure comprising an anthraquinone moiety and a novel aromatic diketocarboxylic acid subunit. On account of its hydroxylated aromatic diketo structure, the compound is able to undergo cyclization to form spiroketal lactones, whose structure type and ring system is previously undescribed and thus hitherto uninvestigated.
In addition to mumbaistatin, fermentation of the organism Streptomyces sp. DSM1 1641 also gives rise to juglomycin-type naphthaquinone antibiotics, in particular juglomycin D, C14H12O712), in concentrations some hundreds of times greater. The quasi-dimerization product juglorubin13), C28H17NaOn, has also been isolated from cultures of Streptomyces sp. DSM1 1641 and identified. In the case of the structurally related nanaomycins A and B, S. Omura et al. used a l-13C-acetate feeding experiment in Streptomyces rosa var. notoensis1^to demonstrate that the biosynthesis of naphthoquinone antibiotics proceeds via polyketides.
A similar mechanism has been postulated for the formation of the juglomycins15), so there can be assumed to be a suitable biosynthetic pathway to mumbaistatin C28H20O12. One plausible mechanism would be condensation of a molecule ofjuglomycin with another C14 polyketide moiety, formed in abundance by the culture as a precursor for juglomycin biosynthesis. The outstanding property of the product mumbaistatin is its very strong inhibitory action on glucose-6-phosphate translocase (G-6-P-T1). With an IC50 of 5 nM, it is the most powerful inhibitor4' 1 1} described to date. The high activity of mumbaistatin is associated with the open aromatic diketocarboxylic acid structure, the activity of the cyclized lactone spiroketal forms being some three orders of magnitude weaker. The only other examples so far reported in the literature are the weakinhibitor chlorogenic acid16), APR. 2001 its much more active synthetic derivatives, and kodaistatin17).
Kodaistatin, which is isolated from Aspergillus terreus cultures, inhibits G-6-P-T1 even at submicromolar concentrations. Both compounds described contain polyhydroxylated ring systems. Mumbaistatin, which has nowbeen fully characterized, shows no structural similarities with previously reported inhibitors.
